Market capitalization | $208.25b |
Enterprise Value | $225.86b |
PER (TTM) P/E ratio | 14.35 |
EV/FCF (TTM) EV/FCF | 17.76 |
EV/Sales (TTM) EV/Sales | 4.64 |
P/S ratio (TTM) P/S ratio | 4.28 |
P/B ratio (TTM) P/B ratio | 5.47 |
Dividend yield | 3.51% |
Last dividend (FY24) | $3.74 |
As a Free StocksGuide user, you can view scores for all 6,952 stocks worldwide.
28 Analysts have issued a Novartis ADR forecast:
28 Analysts have issued a Novartis ADR forecast:
Mar '24 |
+/-
%
|
||
Turnover | 11,829 11,829 |
9%
9%
|
|
Gross income | 8,699 8,699 |
2%
2%
|
|
EBITDA | 4,943 4,943 |
7%
7%
|
EBIT (operating result) EBIT | 3,629 3,629 |
10%
10%
|
Net profit | 2,688 2,688 |
17%
17%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Head office | Switzerland |
CEO | Vasant Narasimhan |
Employees | 76,057 |
Founded | 1996 |
Website | www.novartis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.